Search Results
Your search for ,dUe matches 5408 pages
Showing 501 - 550UICC Outlines Antimicrobial Resistance in Cancer Treatment
Marking World Antimicrobial Awareness Week (taking place November 18 to 24), the Union for International Cancer Control (UICC) emphasized the danger that drug resistance poses to individuals who are particularly vulnerable to infection, such as people living with cancer. There has been substantial...
Short Course of Radiotherapy With Concurrent Radiation Boost for High-Risk, Early-Stage Breast Cancer
A 3-week course of radiation therapy including a concomitant boost of radiation to the surgical site appears to be as safe and effective as 4 to 6 weeks of radiation therapy given with a sequential boost of radiation for patients with early-stage breast cancer who have a high risk of recurrence....
The NordICC Trial: The Devil Is in the Details
Colorectal cancer ranks third among cancer deaths in both men and women in the United States, with an estimated 150,000 new cases and 52,000 deaths anticipated in 2022.1 Colorectal cancer rates have declined by approximately 2% per year from 2014 to 2018 in people older than age 50, which is...
Gradual Increase in Daily Activity With Psychological Therapies May Improve Mental and Physical Health for Patients and Survivors of Breast Cancer
Patients and survivors of breast cancer may have better mental health, physical health, and quality of life when taking part in a “behavioral graded activity” in combination with psychological therapies, according to a new study published by Lahousse et al in the European Journal of Cancer. The new ...
CAR T-Cell Therapy Outcomes Similar Across Different Socioeconomic Levels Among Patients With Pediatric ALL
Although socioeconomic status often influences survival outcomes, pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL) who were living in poverty and were treated with CAR T-cell therapy achieved similar overall survival and were equally likely to achieve a complete...
Dabrafenib in Combination With Trametinib for Unresectable or Metastatic Solid Tumors With BRAF V600E Mutation
On June 22, 2022, dabrafenib in combination with trametinib was granted accelerated approval for treatment of adult and pediatric patients (aged 6 and older) with unresectable or metastatic solid tumors with BRAF V600E mutation whose disease progressed following prior treatment and who have no...
Durvalumab Plus Chemotherapy in Advanced Biliary Tract Cancer
On September 2, 2022, durvalumab was approved for use in combination with gemcitabine/cisplatin for the treatment of patients with locally advanced or metastatic biliary tract cancer.1 Supporting Efficacy Data Approval was based on findings in the double-blind TOPAZ-1 trial (ClinicalTrials.gov...
New Research Highlights Disparities in Receipt of Guideline-Concordant Treatment Among Patients With Ovarian Cancer
New research examining whether patients with ovarian cancer were receiving care concordant with the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) found clear disparities based on patients’ race, ability to pay, and access to specialists and...
New Phase I/II Data on the CD40 Antibody Sotigalimab in Combination With Pembrolizumab in Patients With Metastatic Melanoma
New data from an ongoing phase II trial evaluating first-line intratumoral administration of sotigalimab, a CD40 agonist antibody, in combination with systemic pembrolizumab, an anti–PD-1 antibody, in metastatic melanoma was presented by Bentebibel et al at the Society for Immunotherapy of Cancer...
FDA Approves Brentuximab Vedotin in Combination With Chemotherapy for Pediatric Patients With Classical Hodgkin Lymphoma
On November 10, the U.S. Food and Drug Administration (FDA) approved the CD30-directed antibody-drug conjugate brentuximab vedotin (Adcetris) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients aged 2 years and older with previously...
My White Coat Doesn’t Fit
There I was, crying once again all the way from the hospital’s parking lot to my apartment, into the shower, and while trying to fall asleep. This had become the norm during my internal medicine residency. For years, I tried hard every day to be someone else to fit in. It started with off-hand...
Yuan Yuan, MD, PhD, Joins Cedars-Sinai Cancer Medical Center as Director of Breast Oncology
Cedars-Sinai Cancer Medical Center recently announced the appointment of Yuan Yuan, MD, PhD, a breast medical oncologist and physician scientist who specializes in triple-negative breast cancer and breast cancer immunotherapy, as Director of Breast Oncology. Finding Cutting-Edge Therapies...
TROPiCS-02: Efficacy of Sacituzumab Govitecan Within HER2-Negative Subsets of Breast Cancer
In a post hoc analysis of the phase III TROPiCS-02 trial, sacituzumab govitecan-hziy improved efficacy outcomes in HER2-negative immunohistochemistry (IHC) subgroups.1 Results were consistent with those of the intent-to-treat population of hormone receptor–positive/HER2-negative advanced breast...
Lisocabtagene Maraleucel Improves Event-Free Survival in Second-Line Treatment of Relapsed or Refractory LBCL
As reported in The Lancet by Manali Kamdar, MD, of the University of Colorado Cancer Center, Aurora, and colleagues, an interim analysis of the phase III TRANSFORM trial has shown significantly improved event-free survival with second-line lisocabtagene maraleucel vs standard-of-care salvage...
Overall Survival in Two Monarch Trials of Abemaciclib in Advanced Breast Cancer
Overall survival results from two trials of abemaciclib in advanced breast cancer were reported at the European Society for Medical Oncology (ESMO) Congress 2022. Both MONARCH 3 and monarcHER previously met their primary endpoints of progression-free survival. The current results for overall...
Multilayered Approach to Financial Toxicity Solutions for Patients With Cancer and Their Families
With out-of-pocket costs of cancer care exceeding $21 billion in 2019, financial toxicity among patients and their families in the United States has become too prevalent to ignore. In fact, more than 50% of working-age survivors now report at least one material, psychological, or behavioral domain...
ECHELON-1 Shows Benefit for First-Line Brentuximab Vedotin Plus AVD in Advanced Hodgkin Lymphoma
The results of ECHELON-1 were presented by David J. Straus, MD, of Memorial Sloan Kettering Cancer Center, New York, at the 2022 National Comprehensive Cancer Network (NCCN) Annual Congress: Hematologic Malignancies. Dr. Straus said: “It is a great honor and privilege to present updated results...
Global Effort to Eliminate Cervical Cancer: HPV Vaccinations Are Steadily Increasing in the United States, but Barriers Still Exist
To achieve its goal of eliminating cervical cancer, the World Health Organization (WHO) is calling on all countries “to reach and maintain an incidence rate of below 4 per 100,000 women.” Doing so would depend on the following: A total of 90% of girls being fully vaccinated against human...
Lutetium Lu-177 Vipivotide Tetraxetan for PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
On March 23, 2022, the radioligand therapeutic agent lutetium Lu-177 vipivotide tetraxetan was approved for treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who have been treated with an androgen receptor pathway inhibitor ...
Newly Diagnosed AML: Induction to Maintenance
When it is dark enough, you can see the stars.” —Ralph Waldo Emerson Low-intensity therapy for older or unfit patients with acute myeloid leukemia (AML) was introduced in the early 2000s in the form of low-dose cytarabine or hypomethylation therapy (azacitidine or decitabine). Recent studies...
‘TRANSFORMING’ Our Thinking About Second-Line Therapy for High-Risk Large B-Cell Lymphoma: Bring in the CARs
As reported in The Lancet by Kamdar et al,1 and summarized in this issue of The ASCO Post, the international phase III TRANSFORM trial was completed in 184 patients with primary refractory or early (≤ 12 months) relapsed large B-cell lymphoma (LBCL). Patients were randomly assigned to receive...
Indian Trial Explores Addition of Low-Dose Nivolumab to Chemotherapy in Advanced Head and Neck Cancer
In an Indian single-center phase III trial reported in the Journal of Clinical Oncology, Vijay Patil, MBBS, MD, DM, and colleagues found that the addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival in patients with newly diagnosed or recurrent...
Small Study of Experimental Drug to Treat Liver Cancer Shows Evidence of Activity With Manageable Side Effects
A new drug designed to inhibit an enzyme that plays a crucial role in cell division and growth has shown signs of anticancer activity with manageable side effects in patients with liver cancer and up to three lines of previous unsuccessful treatment, according to a new study published by Reig et al ...
Telisotuzumab Vedotin Plus Erlotinib in c-Met Protein–Expressing NSCLC
In a phase Ib trial reported in the Journal of Clinical Oncology, D. Ross Camidge, MD, PhD, and colleagues found that the combination of telisotuzumab vedotin and erlotinib showed activity in c-Met protein–expressing advanced non–small cell lung cancer (NSCLC), including those with an EGFR mutation ...
DeFi Trial: Novel Gamma Secretase Inhibitor Halts Progression of Desmoid Tumors
Patients with rare desmoid tumors may finally have an effective treatment. A first-in-class gamma secretase inhibitor, nirogacestat, led to an improvement in progression-free survival in the phase III DeFi trial. The results were presented during the Presidential Symposium at the European Society...
Expert Point of View: James Larkin, PhD and Andrea Cercek, MD
Invited discussant James Larkin, PhD, a clinical researcher at the Royal Marsden Hospital, London, commented on the findings from NICHE-2.1 “These striking data are consistent with the recent report in locally advanced mismatch repair–deficient [dMMR] rectal cancer from Memorial Sloan Kettering.2...
Negative Phase III Trials May Dampen Enthusiasm for Immunotherapy in the Adjuvant Setting in Kidney Cancer
Three negative phase III trials presented at the European Society for Medical Oncology (ESMO) Congress 2022 may dampen enthusiasm for immunotherapy as adjuvant therapy for renal cell carcinoma (RCC). None of the three trials—CheckMate 914, IMmotion010, and PROSPER—met its primary endpoint.1-3 The...
Focal Adhesion Kinase Inhibitor in Patients With Meningioma and Somatic NF2 Mutations
As reported in the Journal of Clinical Oncology by Priscilla K. Brastianos, MD, PhD, and colleagues, the phase II Alliance A071401 trial showed activity of the focal adhesion kinase (FAK) inhibitor GSK2256098 in patients with recurrent or progressive grade 1 to 3 meningioma and somatic NF2...
The NordICC Trial: The Devil Is in the Details
Colorectal cancer ranks third among cancer deaths in both men and women in the United States, with an estimated 106,000 new cases and 52,000 deaths anticipated in 2022.1 Colorectal cancer rates have declined by approximately 2% per year from 2014 to 2018 in people over the age of 50 years, which is ...
Longer-Term Follow-up From ADAURA Supports Adjuvant Osimertinib as Standard of Care for EGFR-Mutated Stage IB to IIIA NSCLC
With longer-term follow-up, adjuvant treatment with osimertinib led to a 77% reduction in the risk of disease recurrence or death following complete resection vs placebo-treated patients with EGFR-mutated, stage II to IIIA non–small cell lung cancer (NSCLC). Disease-free survival was improved...
Highlights From the ESMO Congress 2022
At this year’s European Society for Medical Oncology (ESMO) Congress, we experienced an eagerly awaited return to normality (or almost), and the quality of the science on display was anything but disappointing: from molecular medicine to treatment de-escalation, from early cancer detection and...
Researchers Discover Differences in Response to Pembrolizumab Among Patients With Endometrial Cancer
Researchers discovered a differential clinical response to pembrolizumab in patients with Lynch-like (mutated) vs methylated microsatellite instability–high endometrial cancer, outlining characteristics of patients who may derive benefit from immune checkpoint blockade antibodies, according to new...
Chemotherapy Outcomes in Noninfant Childhood ALL With 11q23/KMT2A Rearrangements
In a retrospective study reported in the Journal of Clinical Oncology, Attarbaschi et al described outcomes in patients with noninfant childhood acute lymphoblastic leukemia (ALL) and 11q23/KMT2A rearrangements treated with chemotherapy regimens between 1995 and 2010. Study Details The study...
Neoadjuvant Immunotherapy With Relatlimab and Nivolumab in Stage III Melanoma
The combination of immune checkpoint inhibitors relatlimab and nivolumab for patients with stage III melanoma given before surgery was safe and completely cleared all viable tumor in 57% of patients in a phase II study, according to findings published by Amaria et al in Nature. In addition to...
Addition of Bemarituzumab to mFOLFOX in FGFR2b-Selected Gastric or Gastroesophageal Junction Adenocarcinoma
In the phase II FIGHT trial reported in The Lancet Oncology, Zev A. Wainberg, MD, and colleagues found numerically better progression-free survival with the addition of the anti-FGFR2b antibody bemarituzumab to mFOLFOX (modified fluorouracil, leucovorin, and oxaliplatin) in patients with...
Rogaratinib vs Chemotherapy in Previously Treated Patients With Advanced Urothelial Carcinoma and FGFR1/3 mRNA Overexpression
As reported in the Journal of Clinical Oncology by Cora N. Sternberg, MD, and colleagues, interim analysis of the phase II portion of the phase II/III FORT-1 trial has shown similar objective response rates with the oral FGFR1–4 inhibitor rogaratinib vs chemotherapy in previously treated patients...
Addition of Cediranib to Olaparib for Metastatic Castration-Resistant Prostate Cancer
As reported in the Journal of Clinical Oncology by Kim et al, the phase II National Cancer Institute 9984 trial has shown prolonged radiographic progression-free survival with the addition of cediranib to olaparib in patients with metastatic castration-resistant prostate cancer. Study Details In...
Concurrent Bevacizumab and Reirradiation vs Bevacizumab Alone in Recurrent Glioblastoma
As reported in the Journal of Clinical Oncology by Christina I. Tsien, MD, and colleagues, the phase II NRG Oncology/RTOG1205 trial has shown improved progression-free—but not overall—survival with concurrent bevacizumab and reirradiation vs bevacizumab alone in patients with recurrent...
3-Week Course of Radiotherapy With Concurrent Radiation Boost Found to Be Safe and Effective for Patients With Early-Stage Breast Cancer and Elevated Risk of Recurrence
A 3-week course of radiation therapy is as safe and effective as 4 to 6 weeks of treatment for patients with early-stage breast cancer who have a higher risk of having their tumors recur, results of a randomized phase III clinical trial show. Delivering fewer, but higher, doses of radiation...
Response-Adapted Ultra–Low Dose Radiation Achieves Complete Response in Majority of Patients With Orbital Indolent B-Cell Lymphomas
Using a novel response-adapted ultra–low dose radiation therapy strategy, researchers at The University of Texas MD Anderson Cancer Center observed a 90% complete response rate in patients with orbital indolent B-cell lymphomas. Results were presented by Pinnix et al at the 2022 American Society...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Austria
The Republic of Austria is a high-income, landlocked country in south-central Europe and has been a member of the European Union since 1995.1 Vienna, the capital city of nearly 2 million people, is regularly ranked among the most livable cities in the world.2 The total population of Austria is more ...
For William L. Dahut, MD, a Career of Service in Oncology
In this installment of the Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with William L. Dahut, MD, who is currently serving as Chief Scientific Officer for the American Cancer Society (ACS). In this role, Dr. Dahut manages all pieces of the organization’s discovery work,...
Negative Phase III Trials May Dampen Enthusiasm for Immunotherapy in the Adjuvant Setting in Kidney Cancer
Three negative phase III trials presented at the European Society for Medical Oncology (ESMO) Congress 2022 may dampen enthusiasm for immunotherapy as adjuvant therapy for renal cell carcinoma (RCC). None of the three trials—CheckMate 914, IMmotion010, and PROSPER—met its primary endpoint.1-3 The...
Why Are Young Adult Women Developing Later-Stage, More Aggressive Breast Cancer Than Older Women?
It has been well documented that breast cancer is the most common malignancy in adolescent and young adult (AYA) women aged 15 to 39 years, accounting for 30% of cancers among this population.1 In addition, 5.6% of all invasive breast cancers occur in AYA women.1 A presentation by Rebecca H....
Adding SBRT to Sorafenib May Improve Survival and Time to Disease Progression in Patients With Advanced HCC
Adding stereotactic body radiation therapy (SBRT) to systemic therapy with sorafenib for patients with advanced hepatocellular carcinoma (HCC) may extend overall survival and delay tumor progression without compromising patients’ quality of life, findings from the randomized phase III NRG...
Maternal Deaths From Cancer Worldwide Have Led to Approximately 1 Million New Maternal Orphans
In 2020, 4.4 million women died from cancer worldwide, leaving behind an estimated 1.04 million maternal orphans (defined as children aged 18 years and younger who have lost their mother), according to the results from a study by Guida et al presented during a press conference at the Union for...
Intensive Chemoresection With Mitomycin to Reduce the Need for Surgical Procedures in Patients With Recurrent Non–Muscle-Invasive Bladder Cancer
In a Danish study (DaBlaCa-13) reported in the Journal of Clinical Oncology, Lindgren et al found that short-term intensive chemoresection with mitomycin reduced the need for surgical procedures in patients with recurrent non–muscle-invasive bladder cancer. Study Details The trial was conducted at...
First-Line Nivolumab/Ipilimumab vs Chemotherapy in Metastatic NSCLC Without EGFR or ALK Alterations: 5-Year Survival
As reported in the Journal of Clinical Oncology by Julie R. Brahmer, MD, MSc, FASCO, and colleagues, a 5-year analysis of the phase III CheckMate 227 trial showed improvement in overall survival with first-line nivolumab/ipilimumab vs platinum-doublet chemotherapy, at ≥ 3 years after cessation of...
TROPiCS-02 Sacituzumab Govitecan Effective in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
For advanced breast cancer that is hormone receptor–positive and HER2-negative, sacituzumab govitecan-hziy significantly reduced the risk of disease progression by 34% over physician’s choice of treatment, based on the results of the phase III TROPiCS-02 trial.1 The heavily pretreated patients in...
Breast Cancer 2021–2022 Almanac
The past year has seen an unprecedented number of practice-changing advances across all three major breast cancer subtypes. For patients with early-stage triple-negative breast cancer, neoadjuvant chemotherapy plus pembrolizumab firmly entered the standard of care based on improvements in...
